Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Support Care Cancer ; 23(12): 3625-32, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26298333

ABSTRACT

Antiresorptive therapies are used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease related to breast cancer, prostate cancer, and other solid tumors. This review highlights the central role of nurses in supporting and educating advanced cancer patients regarding the consequences of bone metastases and SREs, including therapy management options. Contemporary clinical journals reporting evidence-based studies were reviewed. SREs associated with bone metastases can significantly impact the quality of life of advanced cancer patients. Denosumab therapy, an advancement in antiresorptive treatments, significantly prevents and delays the time to develop SREs. In the multifaceted approach required for successful and consistent management of SREs associated with bone metastases, antiresorptive therapies can play a central role in maintaining the functional independence of patients through the prevention of debilitating SREs, thereby preserving quality of life.


Subject(s)
Bone Neoplasms/secondary , Denosumab/therapeutic use , Diphosphonates/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Bone Neoplasms/physiopathology , Denosumab/administration & dosage , Diphosphonates/administration & dosage , Female , Humans , Male , Nursing , Quality of Life , Treatment Outcome
2.
Magn Reson Imaging ; 33(10): 1267-1273, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26284600

ABSTRACT

PURPOSE: To assess the value of semi-automated segmentation applied to diffusion MRI for predicting the therapeutic response of liver metastasis. METHODS: Conventional diffusion weighted magnetic resonance imaging (MRI) was performed using b-values of 0, 150, 300 and 450s/mm(2) at baseline and days 4, 11 and 39 following initiation of a new chemotherapy regimen in a pilot study with 18 women with 37 liver metastases from primary breast cancer. A semi-automated segmentation approach was used to identify liver metastases. Linear regression analysis was used to assess the relationship between baseline values of the apparent diffusion coefficient (ADC) and change in tumor size by day 39. RESULTS: A semi-automated segmentation scheme was critical for obtaining the most reliable ADC measurements. A statistically significant relationship between baseline ADC values and change in tumor size at day 39 was observed for minimally treated patients with metastatic liver lesions measuring 2-5cm in size (p=0.002), but not for heavily treated patients with the same tumor size range (p=0.29), or for tumors of smaller or larger sizes. ROC analysis identified a baseline threshold ADC value of 1.33µm(2)/ms as 75% sensitive and 83% specific for identifying non-responding metastases in minimally treated patients with 2-5cm liver lesions. CONCLUSION: Quantitative imaging can substantially benefit from a semi-automated segmentation scheme. Quantitative diffusion MRI results can be predictive of therapeutic outcome in selected patients with liver metastases, but not for all liver metastases, and therefore should be considered to be a restricted biomarker.


Subject(s)
Breast Neoplasms/pathology , Diffusion Magnetic Resonance Imaging/methods , Image Processing, Computer-Assisted/methods , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Female , Humans , Liver/pathology , Middle Aged , Pilot Projects , ROC Curve , Treatment Outcome
3.
Nutr Cancer ; 62(8): 1142-52, 2010.
Article in English | MEDLINE | ID: mdl-21058203

ABSTRACT

Overweight status is common among women breast cancer survivors and places them at greater risk for metabolic disorders, cardiovascular morbidity, and breast cancer recurrence than nonoverweight survivors. Efforts to promote weight control in this population are needed. The objective of this research was to evaluate the effect of low-fat or low-carbohydrate diet counseling on weight loss, body composition, and changes in metabolic indexes in overweight postmenopausal breast cancer survivors. Survivors (n = 40) were randomized to receive dietitian counseling for a low-fat or a reduced carbohydrate diet for 6 mo. Weight and metabolic measures, including glucose, insulin, HbA1c, HOMA, lipids, hsCRP, as well as blood pressure were measured at baseline, 6, 12 and 24 wk. Dietary intake of fat and carbohydrate was reduced by 24 and 76 g/day, respectively. Weight loss averaged 6.1 (± 4.8 kg) at 24 wk and was not significantly different by diet group; loss of lean mass was also demonstrated. All subjects demonstrated improvements in total/HDL cholesterol ratio, and significant reductions in HbA1c, insulin, and HOMA. Triglycerides levels were significantly reduced only in the low-carbohydrate diet group (-31.1 ± 36.6; P = 0.01). Significant improvements in weight and metabolic indexes can be demonstrated among overweight breast cancer survivors adherent to either a carbohydrate- or fat-restricted diet.


Subject(s)
Breast Neoplasms/therapy , Diet, Carbohydrate-Restricted , Diet, Fat-Restricted , Metabolic Syndrome/epidemiology , Metabolic Syndrome/prevention & control , Overweight/diet therapy , Weight Loss , Aged , Blood Pressure , Body Composition , Body Mass Index , Breast Neoplasms/complications , Female , Humans , Middle Aged , Nutritional Sciences/education , Overweight/physiopathology , Patient Education as Topic , Pilot Projects , Postmenopause , Remission Induction , Risk Factors , Time Factors
4.
J Womens Health (Larchmt) ; 18(12): 2041-7, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20044868

ABSTRACT

AIMS: As the efficacy of treatment for breast cancer has improved, particularly with the use of antiestrogenic therapies, there is an increasing population of long-term breast cancer survivors who seeks care with unique health issues. These patients may be at increased risk for cardiovascular disease (CVD) resulting from excess adiposity and treatment effects. Metabolic syndrome (MetS) and elevated C-reactive protein (CRP), two predictors of CVD, have not been fully evaluated in overweight breast cancer survivors on hormone-modulating agents. METHODS: Anthropometric measures, including weight, height, waist and hip circumferences; clinical laboratory assessments, including lipids, glucose, glycoslyated hemoglobin (HbA1c), insulin, and high sensitivity CRP; and body composition and blood pressure (BP) were collected from overweight breast cancer survivors (n=42). Select measures were used to derive MetS using the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) diagnostic criteria. RESULTS: Participants had a mean body weight of 83.8 kg and body mass index (BMI) of 31.4 kg/m2. Mean fasting glucose (98+/-12.9 mg/dL), HbA1c (6.0+/-0.5 mg/dL), cholesterol (199+/-33.7 mg/dL), and insulin (16+/-3.2 mg/dL) were all at the upper end of the normal range. MetS was diagnosed in 54.8% of overweight postmenopausal breast cancer survivors. CRP was moderately or severely elevated in 90.5% of the population (mean of 5.1+/-5.3 mg/dL). CONCLUSIONS: In our sample, overweight breast cancer survivors commonly have MetS and elevated CRP that place them at increased risk for cardiovascular and other metabolic diseases. If replicated in a larger sample, this warrants close medical monitoring to prevent and reduce morbidity and mortality unrelated to breast cancer.


Subject(s)
Antineoplastic Agents, Hormonal/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/epidemiology , C-Reactive Protein/analysis , Metabolic Syndrome/epidemiology , Survivors/statistics & numerical data , Adult , Aged , Body Mass Index , Breast Neoplasms/blood , Chemotherapy, Adjuvant , Comorbidity , Female , Follow-Up Studies , Humans , Metabolic Syndrome/blood , Middle Aged , Obesity/epidemiology , Risk Factors , Waist Circumference , Women's Health
SELECTION OF CITATIONS
SEARCH DETAIL
...